CD3-HM430B-100μg / 询价
CD3-HM430B-500μg / 询价
CD3-HM430B-500μgx2 / 询价
Biotinylated Human CD30/TNFRSF8 Protein
Recombinant Biotinylated Human CD30/TNFRSF8 Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus.It contains Phe19-Lys379 [Accession | P28908-1].
The protein has a predicted MW of 41.3 kDa. Due to glycosylation, the protein migrates to 70-100 kDa based on Bis-Tris PAGE result.
> 95% as determined by Bis-Tris PAGE
> 95% as determined by HPLC
Less than 1EU per μg by the LAL method.
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
-20 to -80°C for 12 months as supplied from date of receipt.
-80°C for 3 months after reconstitution.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Biotinylated CD30 on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
The purity of Biotinylated CD30 is greater than 95% as determined by SEC-HPLC.
Immobilized Human CD30 Ligand, His Tag at 5μg/ml (100μl/well) on the plate. Dose response curve for Biotinylated Human CD30, His Tag with the EC50 of 17.5ng/ml determined by ELISA (QC Test).
Immobilized Anti-CD30 Antibody, hFc Tag at 0.5μg/ml (100μl/well) on the plate. Dose response curve for Biotinylated Human CD30, His Tag with the EC50 of 11.5ng/ml determined by ELISA.
The transmembrane receptor CD30 (TNFRSF8) and its ligand CD30L (CD153, TNFSF8) are members of the tumor necrosis factor (TNF) superfamily and display restricted expression in subpopulations of activated T-and B-cells in nonpathologic conditions. CD30 expression is upregulated in various hematological malignancies, including Reed-Sternberg cells in Hodgkin's disease (HD), anaplastic large cell lymphoma (ALCL) and subsets of Non-Hodgkin's lymphomas (NHLs).
CD30; CD30KI-1; CD30L receptor; TNFRSF8; D1S166EKi-1; CD30KI-1
(1) Oflazoglu E, Grewal IS, Gerber H. Targeting CD30/CD30L in oncology and autoimmune and inflammatory diseases. Adv Exp Med Biol. 2009;647:174-85. doi: 10.1007/978-0-387-89520-8_12. PMID: 19760074.
